Who audits VRTX? — Ernst & Young LLP
VERTEX PHARMACEUTICALS INC / MA is audited by Ernst & Young LLP. Most recent audit opinion is clean (unqualified), dated 2026-02-13.
Opinion — Cited Language
“In our opinion, Vertex Pharmaceuticals Incorporated (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2025, based on the COSO criteria.We also have audited, in accordance with the standards of the Public Company Accounting O…”
Source Filing
What VRTX's Auditor Relationship Tells You
The independent auditor signs off on a public company's financial statements every year — issuing an opinion on whether those statements present fairly the company's financial position. Auditor identity, tenure, and opinion type are structural risk signals that institutional investors evaluate before relying on any reported numbers. For VERTEX PHARMACEUTICALS INC / MA, the current auditor is Ernst & Young LLP.
Auditor tenure is one of the most-watched signals. Very short tenure (under 3 years) can signal a recent change — sometimes routine, sometimes prompted by audit disagreements or fee disputes. Very long tenure (over 20 years) can raise independence concerns under SEC rotation guidance, though there is no mandatory rotation rule in the United States.
Opinion type is the binary signal. A clean unqualified opinion is what investors expect; any deviation — explanatory paragraph, going-concern doubt, qualified opinion — is a material disclosure that should be read carefully. VERTEX PHARMACEUTICALS INC / MA's most recent audit opinion is classified as Clean (Unqualified). Standard unqualified opinion — auditor concurs with management presentation.
For broader context on VRTX's risk profile, see the VRTX Overview, the Going Concern page, or the Dilution page.